CrossrefInfokarte
LCZ696, an Angiotensin–neprilysin Inhibitor Versus Enalapril in Heart Failure – Summary of PARADIGM-HF Results
European Journal of Arrhythmia & Electrophysiology · 2016
DOI: 10.17925/ejae.2016.02.01.14 ↗Abstract
This editorial summarises important findings from the PARADIGM-HF study. PARADIGM-HF indicated that the angiotensin receptorneprilysin inhibitor, LCZ696, is superior to enalapril in reducing the risks of cardiovascular death and of hospitalisation for heart failure in patients with heart failure and reduced ejection fraction.
EUVIMED